ATXI on OTC
AVENUE THERAPEUTICS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Northwest Biotherapeutics, Perspective Therapeutics, Inc. or CANNAPHARMARX, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development74¢$1.0M
- Other costs26¢$365.0K
- Income tax0¢$2.0K
Out of $1.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Other revenue | $1.4M | $0 |
| Research and development | $1.0M | $6.6M |
| General and administrative | $3.7M | $4.6M |
| Gain on sale of Baergic | -$203.0K | $0 |
| Total operating expenses | -$4.5M | -$11.3M |
| Loss from operations | -$3.1M | -$11.3M |
| Interest income | -$121.0K | -$176.0K |
| Loss on common stock warrant liabilities | $0 | $759.0K |
| Change in fair value of warrant liability | -$15.0K | -$170.0K |
| Net loss | -$2.9M | -$11.7M |
| Net loss attributable to non-controlling interest | -$38.0K | -$44.0K |
| Net loss attributable to common stockholders | -$2.9M | -$11.7M |
| Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) | -$0.93 | -$15.79 |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 3.1M shares | 1.3M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-04-30 |
|---|---|---|---|
| Cash and cash equivalents | $2.9M | $2.6M | |
| Prepaid expenses and other current assets | $76.0K | $78.0K | |
| Total assets | $2.9M | $2.7M | |
| Warrant liability | $1.0K | $16.0K | |
| Total current liabilities | $1.1M | $816.0K | |
| Total liabilities | $1.1M | $816.0K | |
| Preferred stock | $0 | $0 | |
| Common shares, 200,000,000 shares authorized, 3,183,558 and 2,108,670 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Additional paid-in capital | $107.3M | $105.4M | |
| Accumulated deficit | -$105.5M | -$102.6M | |
| Total stockholders equity attributed to the Company | $1.8M | $2.8M | |
| Non-controlling interests | $0 | -$941.0K | |
| Total stockholders equity | $1.8M | $1.9M | |
| Total liabilities and stockholders equity | $2.9M | $2.7M | |
| Preferred Stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred Stock, shares issued (in shares) | 250.0K shares | 250.0K shares | |
| Preferred Stock, shares outstanding (in shares) | 250.0K shares | 250.0K shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 3.2M shares | 2.1M shares | |
| Common stock, shares outstanding (in shares) | 3.2M shares | 2.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$2.9M | -$11.7M |
| Share based compensation | $665.0K | $1.2M |
| Loss on common stock warrant liabilities | $0 | $759.0K |
| Change in fair value of warrant liability | -$15.0K | -$170.0K |
| Issuance of Stock Under Founders Agreement | $76.0K | -$167.0K |
| Common Stock, Issued to Fortress, Value | $55.0K | $827.0K |
| License Expenses Paid In Kind | $0 | $6.0K |
| Gain on repurchase of common stock held by AnnJi | -$4.0K | $0 |
| Issuance of common stock of subsidiary | $37.0K | $0 |
| Prepaid expenses and other current assets | $2.0K | -$11.0K |
| Net cash and cash equivalents used in operating activities | -$1.8M | -$9.0M |
| Proceeds from ATM sales of common stock, net of issuance costs | $2.1M | $1.6M |
| Proceeds from exercise of warrants | $0 | $9.4M |
| Warrant exercise transaction costs | $0 | -$1.2M |
| Net cash provided by financing activities | $2.1M | $9.8M |
| Net change in cash and cash equivalents | $261.0K | $811.0K |
| Baergic deconsolidation | -$1.0K | $0 |
| Issuance of common shares - Founders Agreement | $55.0K | $827.0K |
Recent filings
- Aug 7, 202610-Q
- May 8, 202610-Q
- Mar 30, 202610-K
- Feb 23, 20268-K
- Feb 17, 2026SCHEDULE 13G/A
- Jan 6, 20264
- Jan 6, 2026SCHEDULE 13D/A
- Dec 31, 20258-K
- Dec 16, 2025EFFECT
- Dec 15, 2025RW
- Dec 15, 2025POS AM
- Dec 5, 2025DEF 14A
- Nov 18, 20258-K
- Nov 13, 202510-Q
- Nov 12, 20258-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10